TSLP and asthma: However, it is interesting to note that airway hyperresponsiveness to mannitol was significantly more reduced with tezepelumab than with placebo, indicating that anti-TSLP strategy could have additional benefits in asthma beyond reducing type 2 airway inflammation [48▪▪].